Neuphoria Therapeutics Inc. (NASDAQ:NEUP) Sees Large Decline in Short Interest

Posted by Brenda Bartman on Oct 29th, 2026

Neuphoria Therapeutics Inc. (NASDAQ:NEUP – Get Free Report) saw a large decline in short interest in the month of October. As of October 15th, there was short interest totaling 6,429 shares, a decline of 67.9% from the September 30th total of 20,022 shares. Approximately 0.1% of the shares of the company are sold short. Based on an average daily volume of 16,447 shares, the short-interest ratio is presently 0.4 days.

Hedge Funds Weigh In On Neuphoria Therapeutics

Several hedge funds have recently made changes to their positions in the stock. ADAR1 Capital Management LLC purchased a new stake in Neuphoria Therapeutics in the second quarter valued at approximately $131,000. AdvisorShares Investments LLC grew its stake in Neuphoria Therapeutics by 15.8% in the 1st quarter. AdvisorShares Investments LLC now owns 155,367 shares of the company’s stock worth $632,000 after buying an additional 21,173 shares in the last quarter. Finally, Merck & Co. Inc. bought a new position in shares of Neuphoria Therapeutics in the 2nd quarter worth $43,818. 15.90% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on NEUP. Wall Street Zen upgraded shares of Neuphoria Therapeutics to a “hold” rating in a report on Saturday, July 25th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Neuphoria Therapeutics in a research note on Thursday, August 27th. Two investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Neuphoria Therapeutics has a consensus rating of “Reduce” and an average target price of $7.00.

Check Out Our Latest Report on Neuphoria Therapeutics

Neuphoria Therapeutics Price Performance

NASDAQ:NEUP traded down $0.30 on Thursday, reaching $3.06. 70,086 shares of the company’s stock were exchanged, compared to its average volume of 87,639. The firm has a market cap of $16.56 million, a price-to-earnings ratio of -0.49 and a beta of 0.75. Neuphoria Therapeutics has a 52 week low of $3.03 and a 52 week high of $5.53. The stock has a fifty day simple moving average of $3.61 and a 200-day simple moving average of $4.16.